



Ocular Therapeutix™ to Participate in Three Conferences in November 2015

October 28, 2015

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 28, 2015-- Ocular Therapeutix™, Inc.(NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will participate in three upcoming conferences in November including:

- **Citi 2015 Global Healthcare 1x1 Conference**

Wednesday, November 4, 2015

The New York Palace Hotel, New York, NY

- **Ophthalmology Innovation Summit (OIS) at the American Society of Ophthalmology (AAO) 2015**

Presentation: Thursday, November 12, 2015 at 8:30 a.m. Pacific Time

Planet Hollywood Resort, Las Vegas, NV

- **Stifel 2015 Healthcare Conference**

Presentation: Tuesday, November 17, 2015 at 11:45 a.m. Eastern Time

The New York Palace Hotel, New York, NY

A live audio webcast of the corporate presentation at the Stifel 2015 Healthcare Conference can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for two weeks following the presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and Phase 2 clinical development for glaucoma and inflammatory dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151028006592/en/>

Source: Ocular Therapeutix, Inc.

Investors

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com